Abcuro Inc. has raised a $200 million Series C financing to fund late-stage development and support commercial launch ...

US biotech Abcuro has reeled in $200 million in third-round financing that should allow it to complete its pivotal trial of ...

The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.

New research examining the skeletal muscle cells of patients with inclusion body myositis (IBM) has revealed that the nucleic acid-binding protein TDP-43, which is normally restricted to the ...

Now, the veteran guitarist and singer-songwriter is making medical history as he bravely battles inclusion body myositis. IBM ...

Funding was led by New Enterprise Associates, with participation from Foresite Capital and multiple other investors.

Sanofi-backed Abcuro has secured $200 million in series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle ...

The positive predictive value (PPV) of myositis antibodies for diagnosing myositis and its related conditions differs by individual antibody type. Greater diagnostic accuracy is associated with ...

NEWTON, MA, USA I 12, 2025 I Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and ...

Exposures to silica dust, solvents or heavy metals increase the likelihood of developing various forms of myositis, ...

This latest tour joins Frampton’s recent run of shows following a diagnosis of inclusion body myositis (IBM), a degenerative disease of the muscles, in 2019. After a brief flirting with a ...